Please use this identifier to cite or link to this item: https://repositorio.uca.edu.ar/handle/123456789/8802
Título : Melatonin : clinical perspectives in neurodegeneration
Autor : Cardinali, Daniel Pedro 
Palabras clave : ENFERMEDAD DE ALZHEIMERENFERMEDAD DE PARKINSONENFERMEDADES NEUROGENERATIVASENVEJECIMIENTOMELATONINANEURODEGENERACIONESTRES OXIDATIVO
Fecha de publicación : 2019
Editorial : Frontiers
Cita : Cardinali DP. Melatonin : clinical perspectives in neurodegeneration [en línea]. Frontiers in Endocrinology. 2019;10. doi:10.3389/fendo.2019.00480 Disponible en: https://repositorio.uca.edu.ar/handle/123456789/8802
Resumen : Abstract: Prevention of neurodegenerative diseases is presently a major goal for our Society and melatonin, an unusual phylogenetically conserved molecule present in all aerobic organisms, merits consideration in this respect. Melatonin combines both chronobiotic and cytoprotective properties. As a chronobiotic, melatonin can modify phase and amplitude of biological rhythms. As a cytoprotective molecule, melatonin reverses the low degree inflammatory damage seen in neurodegenerative disorders and aging. Low levels of melatonin in blood characterizes advancing age. In experimental models of Alzheimer's disease (AD) and Parkinson's disease (PD) the neurodegeneration observed is prevented by melatonin. Melatonin also increased removal of toxic proteins by the brain glymphatic system. A limited number of clinical trials endorse melatonin's potentiality in AD and PD, particularly at an early stage of disease. Calculations derived from animal studies indicate cytoprotective melatonin doses in the 40-100 mg/day range. Hence, controlled studies employing melatonin doses in this range are urgently needed. The off-label use of melatonin is discussed.
URI : https://repositorio.uca.edu.ar/handle/123456789/8802
ISSN : 1664-2392
Disciplina: MEDICINA
DOI: 10.3389/fendo.2019.00480
Derechos: Acceso abierto
Appears in Collections:Artículos

Files in This Item:
File Description SizeFormat
melatonin-clinical-perspectives-neurodegeneration.pdf622,58 kBAdobe PDFThumbnail
View/Open
Show full item record

Page view(s)

86
checked on Feb 24, 2021

Download(s)

67
checked on Feb 24, 2021

Google ScholarTM

Check


Altmetric


This item is licensed under a Creative Commons License Creative Commons